AngioDynamics (ANGO) Getting Somewhat Positive News Coverage, Report Shows

News headlines about AngioDynamics (NASDAQ:ANGO) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. AngioDynamics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 46.5514141945141 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

AngioDynamics (NASDAQ:ANGO) traded up $0.06 during midday trading on Friday, reaching $17.24. 202,676 shares of the company were exchanged, compared to its average volume of 123,485. The firm has a market capitalization of $632.98, a P/E ratio of 24.99, a PEG ratio of 1.77 and a beta of 1.04. AngioDynamics has a 52 week low of $14.80 and a 52 week high of $18.85. The company has a quick ratio of 1.48, a current ratio of 2.34 and a debt-to-equity ratio of 0.17.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.04). The business had revenue of $85.40 million for the quarter, compared to analyst estimates of $86.12 million. AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. The company’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.17 earnings per share. equities analysts predict that AngioDynamics will post 0.65 earnings per share for the current year.

A number of research analysts recently issued reports on the stock. KeyCorp restated a “hold” rating on shares of AngioDynamics in a research report on Friday, September 29th. Zacks Investment Research upgraded shares of AngioDynamics from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Canaccord Genuity restated a “hold” rating and set a $17.00 target price on shares of AngioDynamics in a research report on Sunday, October 8th. Finally, BidaskClub upgraded shares of AngioDynamics from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $18.60.

TRADEMARK VIOLATION NOTICE: This news story was posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/03/angiodynamics-ango-getting-somewhat-positive-news-coverage-report-shows.html.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Insider Buying and Selling by Quarter for AngioDynamics (NASDAQ:ANGO)

What are top analysts saying about AngioDynamics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AngioDynamics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit